Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Munich
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Kyowa Hakko Kirin Co Ltd

+ Add to Watchlist

KY4:GR

11.971 EUR 0.030 0.25%

As of 09:35:46 ET on 05/28/2015.

Snapshot for Kyowa Hakko Kirin Co Ltd (KY4)

Open: 12.290 Day's Range: 11.948 - 12.290 Volume: 0
Previous Close: 12.001 52wk Range: 7.646 - 13.677 1-Yr Rtn: +37.20%

Stock Chart for KY4

No chart data available.
  • KY4:GR 11.948
  • 1D
  • 1M
  • 1Y
12.001
Interactive KY4 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KY4

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 44.6032
Relative P/E vs. DAX -
Earnings Per Share (JPY) (ttm) -
Est. EPS (JPY) (12/2015) 36.3890
Est. PEG Ratio 2.4575
Market Cap (M EUR) 6,901.08
Shares Outstanding (M) 576.48
30 Day Average Volume 51
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.54%
Cash Dividend (JPY) 12.5000
Dividend Ex-Date 06/26/2015
5 Year Dividend Growth 8.64%
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KY4

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for KY4

Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.

Nobuo HanaiPresidentHiroyuki KawaiExecutive Vice President
Kazuyoshi TachibanaManaging Executive OfficerToshifumi MikayamaManaging Executive Officer
More Company Profile & Key Executives for KY4

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil